Stockwatch: Top of the market
This article was originally published in Scrip
Executive Summary
It's something neither a long-only biotech fund manager (who picks stocks because of their growth prospects), nor a biotech analyst would ever say; we are close the top of the market in biotech. This is because, if true, it means that investors who can will take their money away from biotech and rotate from the best performing sectors, to those of comparatively lower value.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.